Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Chronic Lymphocytic Leukemia (CLL)-Pipeline Review, H1 2015

Chronic Lymphocytic Leukemia (CLL)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Chronic Lymphocytic Leukemia (CLL)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Chronic Lymphocytic Leukemia (CLL)-Pipeline Review, H1 2015', provides an overview of the Chronic Lymphocytic Leukemia (CLL)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Lymphocytic Leukemia (CLL)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Chronic Lymphocytic Leukemia (CLL) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Chronic Lymphocytic Leukemia (CLL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Chronic Lymphocytic Leukemia (CLL) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Chronic Lymphocytic Leukemia (CLL)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Chronic Lymphocytic Leukemia (CLL) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

Introduction 7

Chronic Lymphocytic Leukemia (CLL) Overview 8

Therapeutics Development 9

Chronic Lymphocytic Leukemia (CLL)-Therapeutics under Development by Companies 11

Chronic Lymphocytic Leukemia (CLL)-Therapeutics under Investigation by Universities/Institutes 19

Chronic Lymphocytic Leukemia (CLL)-Pipeline Products Glance 22

Chronic Lymphocytic Leukemia (CLL)-Products under Development by Companies 26

Chronic Lymphocytic Leukemia (CLL)-Products under Investigation by Universities/Institutes 38

Chronic Lymphocytic Leukemia (CLL)-Companies Involved in Therapeutics Development 40

Chronic Lymphocytic Leukemia (CLL)-Therapeutics Assessment 129

Drug Profiles 149

Chronic Lymphocytic Leukemia (CLL)-Recent Pipeline Updates 432

Chronic Lymphocytic Leukemia (CLL)-Dormant Projects 610

Chronic Lymphocytic Leukemia (CLL)-Discontinued Products 619

Chronic Lymphocytic Leukemia (CLL)-Product Development Milestones 621

Appendix 630

List of Tables

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2015 26

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL)-Comparative Analysis, H1 2015 27

Number of Products under Development by Companies, H1 2015 29

Number of Products under Development by Companies, H1 2015 (Contd..1) 30

Number of Products under Development by Companies, H1 2015 (Contd..2) 31

Number of Products under Development by Companies, H1 2015 (Contd..3) 32

Number of Products under Development by Companies, H1 2015 (Contd..4) 33

Number of Products under Development by Companies, H1 2015 (Contd..5) 34

Number of Products under Development by Companies, H1 2015 (Contd..6) 35

Number of Products under Investigation by Universities/Institutes, H1 2015 37

Number of Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 38

Comparative Analysis by Late Stage Development, H1 2015 39

Comparative Analysis by Clinical Stage Development, H1 2015 40

Comparative Analysis by Early Stage Development, H1 2015 41

Comparative Analysis by Unknown Stage Development, H1 2015 42

Products under Development by Companies, H1 2015 43

Products under Development by Companies, H1 2015 (Contd..1) 44

Products under Development by Companies, H1 2015 (Contd..2) 45

Products under Development by Companies, H1 2015 (Contd..3) 46

Products under Development by Companies, H1 2015 (Contd..4) 47

Products under Development by Companies, H1 2015 (Contd..5) 48

Products under Development by Companies, H1 2015 (Contd..6) 49

Products under Development by Companies, H1 2015 (Contd..7) 50

Products under Development by Companies, H1 2015 (Contd..8) 51

Products under Development by Companies, H1 2015 (Contd..9) 52

Products under Development by Companies, H1 2015 (Contd..10) 53

Products under Development by Companies, H1 2015 (Contd..11) 54

Products under Investigation by Universities/Institutes, H1 2015 55

Products under Investigation by Universities/Institutes, H1 2015 (Contd..1) 56

Chronic Lymphocytic Leukemia (CLL)-Pipeline by 4SC AG, H1 2015 57

Chronic Lymphocytic Leukemia (CLL)-Pipeline by AbbVie Inc., H1 2015 58

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Acetylon Pharmaceuticals, Inc., H1 2015 59

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Altor BioScience Corporation, H1 2015 60

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Amorfix Life Sciences Ltd., H1 2015 61

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Angstrom Pharmaceuticals, Inc., H1 2015 62

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Aprogen, Inc., H1 2015 63

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Arno Therapeutics, Inc., H1 2015 64

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Astellas Pharma Inc., H1 2015 65

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Astex Pharmaceuticals, Inc., H1 2015 66

Chronic Lymphocytic Leukemia (CLL)-Pipeline by AstraZeneca Plc, H1 2015 67

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Bayer AG, H1 2015 68

Chronic Lymphocytic Leukemia (CLL)-Pipeline by BioInvent International AB, H1 2015 69

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Biothera, Inc., H1 2015 70

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Boehringer Ingelheim GmbH, H1 2015 71

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Bristol-Myers Squibb Company, H1 2015 72

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Celgene Corporation, H1 2015 73

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Cellectis S.A., H1 2015 74

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Cellular Biomedicine Group, Inc., H1 2015 75

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Coherus BioSciences, Inc., H1 2015 76

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Conkwest, Inc., H1 2015 77

Chronic Lymphocytic Leukemia (CLL)-Pipeline by CTI BioPharma Corp., H1 2015 78

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Cyclacel Pharmaceuticals, Inc., H1 2015 79

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Eagle Pharmaceuticals, Inc., H1 2015 80

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Eli Lilly and Company, H1 2015 81

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Emergent BioSolutions Inc., H1 2015 82

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 83

Chronic Lymphocytic Leukemia (CLL)-Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 84

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Genentech, Inc., H1 2015 85

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Genmab A/S, H1 2015 86

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Gilead Sciences, Inc., H1 2015 87

Chronic Lymphocytic Leukemia (CLL)-Pipeline by GlaxoSmithKline Plc, H1 2015 88

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Grupo Ferrer Internacional, S.A., H1 2015 89

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Hospira, Inc., H1 2015 90

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Hutchison MediPharma Limited, H1 2015 91

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Hybrigenics S.A., H1 2015 92

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Igenica Biotherapeutics, Inc., H1 2015 93

Chronic Lymphocytic Leukemia (CLL)-Pipeline by ImmunoGen, Inc., H1 2015 94

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Immunomedics, Inc., H1 2015 95

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Incyte Corporation, H1 2015 96

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Infinity Pharmaceuticals, Inc., H1 2015 97

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Innate Pharma SA, H1 2015 98

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Innovent Biologics, Inc., H1 2015 99

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Johnson & Johnson, H1 2015 100

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Juno Therapeutics Inc., H1 2015 101

Chronic Lymphocytic Leukemia (CLL)-Pipeline by KaloBios Pharmaceuticals, Inc., H1 2015 102

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Kancera AB, H1 2015 103

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 104

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Kite Pharma, Inc., H1 2015 105

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Lead Discovery Center GmbH, H1 2015 106

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Les Laboratoires Servier SAS, H1 2015 107

Chronic Lymphocytic Leukemia (CLL)-Pipeline by LFB S.A., H1 2015 108

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Lymphocyte Activation Technologies, S.A., H1 2015 109

Chronic Lymphocytic Leukemia (CLL)-Pipeline by MediGene AG, H1 2015 110

Chronic Lymphocytic Leukemia (CLL)-Pipeline by MedImmune, LLC, H1 2015 111

Chronic Lymphocytic Leukemia (CLL)-Pipeline by MENTRIK Biotech, LLC, H1 2015 112

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Merck & Co., Inc., H1 2015 113

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Merck KGaA, H1 2015 114

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 115

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Mirna Therapeutics, Inc., H1 2015 116

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Molecular Templates Inc., H1 2015 117

Chronic Lymphocytic Leukemia (CLL)-Pipeline by MorphoSys AG, H1 2015 118

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Neopharm Ltd., H1 2015 119

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Nimbus Therapeutics, LLC, H1 2015 120

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Novartis AG, H1 2015 121

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 122

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Onyx Pharmaceuticals, Inc., H1 2015 123

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Panacea Biotec Limited, H1 2015 124

Chronic Lymphocytic Leukemia (CLL)-Pipeline by PEP-Therapy SAS, H1 2015 125

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Pharmacyclics, Inc., H1 2015 126

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Portola Pharmaceuticals, Inc., H1 2015 127

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Redx Pharma Plc, H1 2015 128

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Respiratorius AB, H1 2015 129

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Sandoz International GmbH, H1 2015 130

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Sanofi, H1 2015 131

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2015 132

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Simcere Pharmaceutical Group, H1 2015 133

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Sorrento Therapeutics, Inc., H1 2015 134

Chronic Lymphocytic Leukemia (CLL)-Pipeline by SpectraMab GmbH, H1 2015 135

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Spectrum Pharmaceuticals, Inc., H1 2015 136

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Supratek Pharma Inc., H1 2015 137

Chronic Lymphocytic Leukemia (CLL)-Pipeline by TG Therapeutics, Inc., H1 2015 138

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Theravectys S.A., H1 2015 139

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 140

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Tolero Pharmaceuticals, Inc., H1 2015 141

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Tragara Pharmaceuticals, Inc., H1 2015 142

Chronic Lymphocytic Leukemia (CLL)-Pipeline by ViDAC Pharma Ltd., H1 2015 143

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Viralytics Ltd., H1 2015 144

Chronic Lymphocytic Leukemia (CLL)-Pipeline by Zymeworks Inc., H1 2015 145

Assessment by Monotherapy Products, H1 2015 146

Assessment by Combination Products, H1 2015 147

Number of Products by Stage and Target, H1 2015 149

Number of Products by Stage and Mechanism of Action, H1 2015 157

Number of Products by Stage and Route of Administration, H1 2015 163

Number of Products by Stage and Molecule Type, H1 2015 165

Chronic Lymphocytic Leukemia (CLL) Therapeutics-Recent Pipeline Updates, H1 2015 448

Chronic Lymphocytic Leukemia (CLL)-Dormant Projects, H1 2015 626

Chronic Lymphocytic Leukemia (CLL)-Dormant Projects (Contd..1), H1 2015 627

Chronic Lymphocytic Leukemia (CLL)-Dormant Projects (Contd..2), H1 2015 628

Chronic Lymphocytic Leukemia (CLL)-Dormant Projects (Contd..3), H1 2015 629

Chronic Lymphocytic Leukemia (CLL)-Dormant Projects (Contd..4), H1 2015 630

Chronic Lymphocytic Leukemia (CLL)-Dormant Projects (Contd..5), H1 2015 631

Chronic Lymphocytic Leukemia (CLL)-Dormant Projects (Contd..6), H1 2015 632

Chronic Lymphocytic Leukemia (CLL)-Dormant Projects (Contd..7), H1 2015 633

Chronic Lymphocytic Leukemia (CLL)-Dormant Projects (Contd..8), H1 2015 634

Chronic Lymphocytic Leukemia (CLL)-Discontinued Products, H1 2015 635

Chronic Lymphocytic Leukemia (CLL)-Discontinued Products (Contd..1), H1 2015 636

List of Figures

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL), H1 2015 26

Number of Products under Development for Chronic Lymphocytic Leukemia (CLL)-Comparative Analysis, H1 2015 27

Number of Products under Development by Companies, H1 2015 28

Number of Products under Investigation by Universities/Institutes, H1 2015 36

Comparative Analysis by Late Stage Development, H1 2015 39

Comparative Analysis by Clinical Stage Development, H1 2015 40

Comparative Analysis by Early Stage Products, H1 2015 41

Assessment by Monotherapy Products, H1 2015 146

Assessment by Combination Products, H1 2015 147

Number of Products by Top 10 Targets, H1 2015 148

Number of Products by Stage and Top 10 Targets, H1 2015 148

Number of Products by Top 10 Mechanism of Actions, H1 2015 156

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 156

Number of Products by Top 10 Routes of Administration, H1 2015 162

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 162

Number of Products by Top 10 Molecule Types, H1 2015 164

Number of Products by Stage and Top 10 Molecule Types, H1 2015 164

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

4SC AG

AbbVie Inc.

Acetylon Pharmaceuticals, Inc.

Altor BioScience Corporation

Amorfix Life Sciences Ltd.

Angstrom Pharmaceuticals, Inc.

Aprogen, Inc.

Arno Therapeutics, Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals, Inc.

AstraZeneca Plc

Bayer AG

BioInvent International AB

Biothera, Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

Cellectis S.A.

Cellular Biomedicine Group, Inc.

Coherus BioSciences, Inc.

Conkwest, Inc.

CTI BioPharma Corp.

Cyclacel Pharmaceuticals, Inc.

Eagle Pharmaceuticals, Inc.

Eli Lilly and Company

Emergent BioSolutions Inc.

Epirus Biopharmaceuticals, Inc.

F. Hoffmann-La Roche Ltd.

Genentech, Inc.

Genmab A/S

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Grupo Ferrer Internacional, S.A.

Hospira, Inc.

Hutchison MediPharma Limited

Hybrigenics S.A.

Igenica Biotherapeutics, Inc.

ImmunoGen, Inc.

Immunomedics, Inc.

Incyte Corporation

Infinity Pharmaceuticals, Inc.

Innate Pharma SA

Innovent Biologics, Inc.

Johnson & Johnson

Juno Therapeutics Inc.

KaloBios Pharmaceuticals, Inc.

Kancera AB

Karyopharm Therapeutics, Inc.

Kite Pharma, Inc.

Lead Discovery Center GmbH

Les Laboratoires Servier SAS

LFB S.A.

Lymphocyte Activation Technologies, S.A.

MediGene AG

MedImmune, LLC

MENTRIK Biotech, LLC

Merck & Co., Inc.

Merck KGaA

Millennium Pharmaceuticals, Inc.

Mirna Therapeutics, Inc.

Molecular Templates Inc.

MorphoSys AG

Neopharm Ltd.

Nimbus Therapeutics, LLC

Novartis AG

Ono Pharmaceutical Co., Ltd.

Onyx Pharmaceuticals, Inc.

Panacea Biotec Limited

PEP-Therapy SAS

Pharmacyclics, Inc.

Portola Pharmaceuticals, Inc.

Redx Pharma Plc

Respiratorius AB

Sandoz International GmbH

Sanofi

Shanghai Henlius Biotech Co., Ltd.

Simcere Pharmaceutical Group

Sorrento Therapeutics, Inc.

SpectraMab GmbH

Spectrum Pharmaceuticals, Inc.

Supratek Pharma Inc.

TG Therapeutics, Inc.

Theravectys S.A.

Threshold Pharmaceuticals, Inc.

Tolero Pharmaceuticals, Inc.

Tragara Pharmaceuticals, Inc.

ViDAC Pharma Ltd.

Viralytics Ltd.

Zymeworks Inc.

Chronic Lymphocytic Leukemia (CLL) Therapeutic Products under Development, Key Players in Chronic Lymphocytic Leukemia (CLL) Therapeutics, Chronic Lymphocytic Leukemia (CLL) Pipeline Overview, Chronic Lymphocytic Leukemia (CLL) Pipeline, Chronic Lymphocytic Leukemia (CLL) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com